Objective: To determine matrix metalloproteinase2 and survivin expressions in endometrial cancers, their relation to clinical and histologic parameters and to investigate any difference in the expression of these markers between endometrioid and non endometrioid cancers. Methods: Ninetyfive patients with endometrial cancer, were included. Matrix metalloproteinase2 and survivin expressions were analyzed immunohistochemically from paraffinembedded tissues by using specific monoclonal antibodies. Results: Survivin nuclear expression was higher in endometrioid cancer as compared to non endometrioid cancer (p=0.040), but there was no difference for cytoplasmic survivin and matrix metalloproteinase2 expressions between type I and type II carcinomas. Survivin cytoplasmic staining was significantly lower in patients with deep myometrial invasion (p=0.038). Nuclear expression of survivin is decreased in histologic grade 3 tumors compared to grade 1 and 2 tumors (p=0.013), but there is no difference between grade 1 and 2. We did not find any statistically significant difference between survivin or matrix metalloproteinase2 expressions and survival. Conclusion: Survivin and matrix metalloproteinase2 are present in endometrioid and nonendometrioid cancers. Grade 1 and 2 tumors and carcinomas having myometrial invasion less than 50% have higher survivin expression. These results supports that, survivin may play an important role in early stage tumors and early phases of tumor development. We did not find any association between matrix metalloproteinase2 expression and classical prognostic factors in endometrial cancer and both proteins were not associated with survival.
INTRODUCTION
Endometrial cancer is the most common malignancy of the fe male reproductive tract in developed countries [1] . It affects mainly postmenopausal women and only 20% of wo men will be diagnosed before menopause. The prognosis is usually good because approximately 72% of cases are diag no sed at stage I [2] . It has commonly been classified into two major clinicopathologic types, type I and type II [3] . It is currently known that these two types of endometrial car ci nomas show different molecular alterations. The most fre quent early molecular defects of endometrioid carcinomas
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Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance 90 www.ejgo.org are mutations of PTEN, KRas, CTNNB1 (betacatenin) genes and microsatellite instability (MSI), but they rarely exhibit p53 mutations [1, 4, 5] . In contrast, nonendometrioid carcinomas often exhibit p53 tumor suppressor gene mutations and loss of heterozygosity located on several chromosomes, but occasionally have MSI [6, 7] Unfortunately, none of these mo lecular markers are prognostic enough for endometrial cancer, and new prognostic markers are necessary.
Matrix metalloproteinases (MMPs) are a family of zincdepen dent endopeptidases which degrade the extracellular matrix and play an important role in tumor invasion and progression [8] . MMPs are expressed at low levels in normal adult tissues, except in tissues that undergo remodeling such as the cyclic endometrium and the skin during wound healing [911] . Also, MMP2 expression has been shown to be increased in several human neoplasias such as breast, ovary and colon cancers, and it seems to correlate with their invasion and metastatic be haviours [9] . Recently, MMP2 has been demonstrated in en do metrial carcinoma cells but there are only a few studies comparing MMP2 expression between type I and type II en do metrial carcinoma [12, 13] .
Survivin is a novel and structurally unique member of the in hibitor apoptosis (IAP) family of antiapoptotic proteins. Its gene is located on chromosome 17q25 [14] . Unlike other IAP proteins, survivin was found during fetal development, is not detectable in normal adult tissues, and became reexpressed in all of the most common human cancers [15, 16] . Recently, in several studies, overexpression of survivin has been shown to be associated with endometrial carcinoma, but there are con flicting results for the impact on prognosis of endometrial carcinoma [1719] . The nuclear or cytoplasmic expression of sur vivin is controversial. Immunofluorescence studies show e d that survivin was expressed mainly in the nucleus of en do me trial carcinoma cells, whereas previous studies reported that it is restricted to the cytoplasm [18] .
This study aimed to investigate the expression of MMP2 and survivin in surgically treated endometrial cancer patients. MMP2 and survivin expressions were compared in type I and type II tumors, and the correlation of these markers between wellestablished prognostic factors and the relationship with survival were analyzed. [20, 21] . Standard hematoxylin and eosin (H&E)stained sections of formalinfixed, paraffin embedded tumor tissues were reviewed to confirm the histopathologic diagnosis; 73 cases were classified as FIGO stage 1, 6 cases as stage 2 and 16 cases as stage 3. All patients were followed up until death or a median of 39 months (range, 9 to 151 months).
MATERIALS AND METHODS

Patients and specimens
Immunohistochemistry
Five mm sections were taken onto polyL lysincoated slides from each representative archival paraffinembedded tumor tissue for immunohistochemical staining. The standard streptavidin biotin immunoperoxidase method was performed using the primary antibodies against survivin (1/100, Diagnostic Biosystems, Pleasanton, CA, USA) and MMP2 (1/50, Diagnostic Biosystems). Briefly, sections were deparaffinized in xylene, rehydrated in alcohol series, and immersed in distillated water. Endogenous peroxidase activity was blocked using a 0.3% solution of hydrogen peroxide in phosphatebuffered saline (0.01 mmol/L, pH 7.5) at room temperature for 15 minutes and rinsed with TRIS buffer. After antigen retrieval by heating in 10 mmol/L citrate buffer (pH 6.0) for 30 minutes, primary antibodies were applied for 60 minutes at room temperature and washed in TRIS buffer. Biotinylated secondary antibodies and streptavidin peroxidase complex were added consecutively for 10 minutes at room temperature and washed in TRIS buffer. Peroxidase activity was visualized with 0.03% 33' diaminobenzidine tetrahydrochloride applied for 7 minutes. After rinsing in deionized water and counterstaining in Mayer's hematoxylin, the slides were dehydrated and mounted. Appropriate tissue sections as positive controls for each primary antibody were also stained simultaneously. As a negative control, sections were processed in the absence of primary antibody.
Immunohistochemical evaluation
Immunohistochemical staining in tumor cells was evaluated www.ejgo.org 91 in a semiquantitative fashion. For the survivin antibody, both cytoplasmic and nuclear staining were observed and evalu a te d. For MMP2, only cytoplasmic staining was observed and evaluated. The degree of staining for survivin and MMP2 was evaluated by scoring on a scale from 0 to 4 for intensity (I) and for distribution (D). Tissues with IxD equal to 0 were consi der ed negative, those with less than or equal to 4 were weakly po si tive, and those with greater than 4 were strongly positive [22] . Results were also further simplified as positive and negative.
Statistical analysis
Data analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). The relationship between immunohisto che mical scores, tumor stage and histologic and nuclear grade was investigated by using the chisquared test. Survival analy ses were calculated by using the KaplanMeier method. The long rank test was used for univariate, and Cox proportional hazards regression model for the multivariate evaluation. The probability level 0.05 or less was chosen to represent statistical significance.
RESULTS
A total of ninetyfive patients with endometrial carcinoma were included in the present study. There were 74 (77.9%) endometrioid (type I) and 21 (22.1%) nonendometrioid (type II) carcinomas. The median age of the patients was 61 years (range, 34 to 87 years). Clinicopathologic characteristics of the cases are shown in Table 1 .
Distribution of MMP2 and survivin staining in 95 endometri al tumors are shown in Table 2 . For survivin, positive cytoplas mic and nuclear immunohistochemical staining was seen in 73.7% and 66.3% respectively, and also MMP2 on 66.3% of all tumors ( Figs. 1 and 2 ). Survivin nuclear expression was higher in endometrioid endometrial carcinoma (EEC) compared to nonEEC (NEEC), and this was statistically significant (p= 0.040), but there was no statistically significant relationship be t ween cytoplasmic survivin and MMP2 expressions be t ween type I and type II carcinomas. Table 3 summarizes the clinicopathologic characteristics of 95 patients with endo me t rial carcinoma and their association with the expression of survivin and MMP2. There was no relationship between Followup data were available for all patients. The median duration of followup was 39 months (range, 9 to 151 months). During the followup, 3 local recurrences, 2 solid organ metastasis, and 3 lymph node metastasis were documented.
Overall mean cumulative survival of the patients was 134.30 ±5.46 months, and the cumulative overall and diseasefree survival rates were 0.822 and 0.821, respectively. The mean survival related to survivin nuclear, cytoplasmic and MMP2 expression is shown in Table 4 . While the mean cumulative survival was 140.96 months in stage I cases, it dropped to 110.22 months in the advanced stage group (p=0.0054). Also, the cumulative survival rates of patients with type I tumors were significantly higher than those of patients with type II tumors (p<0.001). Cox regression analysis showed that stage, grade and histological type have an independent impact on survival. We did not find any statistically significant difference between survivin or MMP2 expressions and survival (p>0.05) ( Table 4) .
DISCUSSION
MMP2 and survivin expressions and their relationships with the clinical behaviors and histologic types of endometrial cancers were investigated in this study. In our present study, MMP2 expression did not show any difference between EEC and NEEC carcinomas. These results confirm those of Graesslin et al. [13] . On the other hand, ShacoLevy et al. [23] found increased MMP2 expression in NEEC as compared to EEC. In another study, Monaghan et al. [12] showed that significantly greater MMP2 expression was present in EEC compared to NEEC. The difference between these two studies could be attributed to the fact that the two study groups were not homogenous in terms of tumor stage and grade. There have been only a few studies investigating the relationship between matrix metalloproteinase expression Values are presented as number (%). MMP, matrix metalloproteinases; MI, myometrial invasion; LVI, lymphovascular invasion. [24, 25] . Di Nezza et al. [26] revealed that MMP 2 and MMP9 expressions in tumor cells are increased in the transition from histologic grade 1 to grades 2 and 3. These results are supported by other studies [13, 25] . On the other hand, Lopata et al. [27] , with use of gelatin zymography, revealed that elevated levels of latent and active forms of MMP2 are detected in uterine lavage samples from patients with endometrial cancer, and they found no significant association between the MMP score and the histologic grade of tumor. Likewise, Honkavuori et al. [28] did not determine any correlation between MMP2 immunostaining and histological grade. These results are consistent with our study. Furthermore, we did not find any correlation between the MMP2 score and the FIGO stage, vascular/lymphatic invasion, or depth of myometrial invasion. These results agree with those of other authors [25, 26, 28, 29] . Graesslin et al. [13] found that high MMP2 expression is correlated with only lymph node metastasis, but that there is no association with other clinical features of endometrial cancer. Their results are in keeping with the study of Iurlaro et al. [30] Survival analyses have been rarely performed in previous studies. Moser et al. [24] , Aglund et al. [25] , and, recently, Honkavuori et al. [28] found no statistically significant correlation between MMP2 expression and overall survival in endometrial cancer. Similarly, in the present study, we did not find any association between survival and the MMP2 staining score. Survivin, a member of the IAP family, has been detected to be over expressed in 60 human cancer types studied, including en dometrial carcinoma [31, 32] . Although some immu no his to chemical studies suggested that survivin expression occurs primarily in the nucleus and partially in the cytoplasm of en do metrial cancer cells, Pallares et al. [33] found that most of the survivin proteins were cytoplasmic. The present study did not determine statistically significant difference be t ween cytoplasmic and nuclear expressions. In a small num ber of previous reports investigating the role of survivin in the endometrial cancer, controversial results have been obtained [17, 18, 3335] . Saitoh et al. [34] demonstrated that levels of survivin mRNA in endometrial cancer samples were significantly higher than the levels that were seen in the nor mal endometrium, and did not show any correlation with his tologic grade of the tumors. Similarly, in their study, Ai et al. [32] showed that survivin protein expression levels were significantly higher in endometrial cancer cells than atypical or normal endometrium, and were not different between type 1 and type 2 endometrial cancers. Also, they did not ob ser ve any association with patient age, tumor grade and stage, and these results were supported by Pallares et al. [33] . In our present study, unlike the results of Ai et al. [32] , survivin nuclear expression was higher in EEC as compared to NEEC. This difference may be due to the nonhomogenous stage dis tribution in type 1 and type 2 patient groups in the above studies including ours. Lehner et al. evaluated survivin mRNA levels in both normal endometrium and endometrial cancer specimens, and suggested that survivin mRNA is not a specific marker of endometrial cancer. In contrast to the studies of Ai et al. [32] and Pallares et al. [33] , Lehner et al. [35] suggested that survivin mRNA expression only correlates with the histologic grade of the tumors. The study of Takai et al. [18] , supporting the results of Lehner et al. [35] , showed that survivin protein expressions within endometrial carcinoma cells were sig ni fi cantly associated with significant clinicopathologic prog no stic parameters and survival rates. Recently, at another im mu no histochemical study of Erkanli et al. [17] , they showed survivin expression to be increased in a spectrum from normal to hyperplastic endometrium and to endometrial cancer. Also, different from Takai et al. [18] , they have reported no correlation between survivin and classical prognostic factors or survival rates in endometrial carcinomas. Eventually these authors concluded that these findings suggest that survivin overexpression is one of the most important factors in the developmental pathway of endometrioid carcinomas [17] . Likewise, in our study, we found that nuclear expression of survivin is decreased in histologic grade 3 tumors compared to both grade 1 and grade 2 tumors, and survivin cytoplasmic expression was significantly lower in patients with deep myo metrial invasion (p=0.038). These results differ from other stu dies, supporting the suggestion in the study of Erkanli et al., and may be explained as survivin expression playing a role in the earlier stages or development of tumor, but not in tumor aggressiveness of it. Also, in our study, we did not find any rela tion between survivin expression and clinical prognostic factors including lymphovascular space involvement and ex tra uterine disease or survival. However, these results are not consistent with the study of Lambropoulou et al. [19] . They found a significant correlation survivin expression with myometrial invasion, histological grade, stage and survival rates. This difference may be due to different staining criteria.
www.ejgo.org 93
In conclusion, differing from those of previous studies, we have shown that in histologic grade 1 and 2 tumors and cases with myometrial invasion less than 50%, survivin expression was found to be higher. These results support the hypothesis that survivin may play an important role in early stage tumors and early phases of tumor development. However, we did not find any association between MMP2 expression and classical www.ejgo.org 95 prognostic factors in endometrial carcinoma, additionally both proteins were not associated with survival. As far as we know our study includes the largest number of cases of both survivin and MMP2 expression in the literature. Further studies with longer followup and larger number of cases are needed.
